Alzheimer’s disease is the most common cause of dementia and the sixth leading cause of death in the United States. It ...

For decades, scientists have focused on amyloid plaques—abnormal clumps of misfolded proteins that accumulate between neurons ...

AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...

Researchers at Northwestern University have made a breakthrough in identifying a way for Alzheimer's disease to be treated ...

A new study suggests a promising alternative to previous attempts to remove the sticky, toxic amyloid beta plaques from brains with Alzheimer's Disease: enhancing the brain's own immune cells to clear ...

Scientists have long been racking their brains for ways to treat Alzheimer’s disease, the most common type of dementia.

Chicago area scientists have identified the genes that drive the process of Alzheimer’s disease and are working to make the drug Lecanemab even better by identifying which genes are active ...

Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial ...

Not the Same. In amyloid-negative people (left) few tangles accumulate over a decade. In amyloid-positives (right), tangles grow faster in women (red) than men (blue). [Courtesy of Gillian Coughlan, ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...